⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
PFE — Pfizer Inc.
Last scan (Nov. 5, 2026): price $30.79, RSI 64.49, relative volume 1.55x, MACD 🟢 Yes, score 52.59.
It's in a bullish underlying trend (above its 200-day average), with an RSI of 64.49 in a neutral zone. The daily MACD confirms bullish momentum, and the price just broke its 20-day high — two short-term technical signals lining up. Relative volume of 1.55x is somewhat above normal. The current price is already above the analysts' average target (-4.4%) — the market is pricing in more than they expect. With a PEG of 13.75, the price already bakes in high growth expectations.
Price chart
PFE
Price: $30.57 · RSI (14): 61.64 · Rel. volume: 0.65x · Breakout: No
- Current price: ($30.57) — solid white line — the latest available closing price.
- Target price: ($29.45) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($25.81) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
PFE
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under…
- Buy 9
- Hold 17
- Sell 2
Average target price: $29.45 (-3.6% vs. current price) · range $25.0 – $36.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
?
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
High: the market is paying a premium, usually because it expects strong growth. If the company doesn't deliver, the price could correct sharply.
?
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
?
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Above 2: even accounting for expected growth, the price looks expensive.
?
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Moderate leverage, normal in many industries.
?
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Healthy margin for most industries.
?
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Pays out a portion of its earnings as cash to shareholders on a recurring basis.
?
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.